MedTrace Logo

Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

NCT06383819 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2025-06-03

No results posted yet for this study

Summary

The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection

Conditions

  • Post-Acute COVID-19 Syndrome
  • Lung Disease With Polymyositis
  • Fibrosis
  • Lung Diseases, Interstitial
  • Lung; Disease, Interstitial, With Fibrosis

Interventions

DRUG

Longidaza®

dose 3000 IU intramuscularly once every 5 days, 15 injections

DRUG

Placebo

intramuscularly once every 5 days, 15 injections

Sponsors & Collaborators

  • NPO Petrovax

    lead INDUSTRY

Principal Investigators

  • Sergey Avdeev, DM · I.M. Sechenov First Moscow State Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06383819 on ClinicalTrials.gov